Abstract
6089 Background: The purpose of this project is to demonstrate how a publicly available data source is used for safety assessments in cancer drug development and commercialization. Methods: Oxaliplatin was approved in August 2002 for second-line use in metastatic colorectal cancer. Peripheral sensory neuropathy commonly occurs with oxaliplatin, and at least 4 cases of autonomic neuropathy (with Lhermitte's sign and urinary retention), have also been reported. We searched the FDA SAERS database, which is comprised predominantly of MedWatch reports filed by physicians, for reports suggesting either of these frequent or infrequent types of neuropathy. Proportional reporting ratios (PRR) were calculated for oxaliplatin relative to other platinum compounds. PRRs > 3.0 are suggestive of a “signal”, but need a larger context to interpret. Results: Relevant PRRs as of March 21, 2003 are shown for MedDRA High Level Terms (HLT) and various Preferred Terms (PT) subsumed under the HLTs. The PRR for oxaliplatin is sta...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
